Iloprost-induced rash.
نویسندگان
چکیده
anecdotally, some clinicians seem to consider LTOT to be an absolute contraindica-tion to intubation. Table 1 summarises the outcomes for intubated patients with chronic obstructive pulmonary disease (COPD) in the COPD and Asthma Outcome Study (CAOS), comparing those who were on LTOT before admission with those who were not. It can be seen that, although the two groups of patients had similar 180-day survival rates, the LTOT group had significantly lower EuroQol scores. These differences partly reflect differences in health status before the onset of the acute episode (at that stage 63% of the LTOT group were housebound, chairbound or bedbound compared with 27% of the rest) and partly the higher proportion of the LTOT group who felt that their health at 180 days was worse than it had been before onset. Nevertheless, in our data, 86% would choose ICU and intubation again. The actual number of patients on LTOT who responded to the follow-up questionnaire was small and the confidence interval wide (58–98%). It is also possible that the small numbers of patients with COPD on LTOT currently being admitted to critical care are atypically positive about invasive procedures , at least in retrospect. Nonetheless, the straightforward interpretation of these data is that, from the perspective of the patient with COPD, intubation is not futile—even for those on LTOT. If so, patient preferences must often be frustrated by limits on the availability of ICU beds. What the threshold should be for intubation in terms of probability of survival and how patients' (or carers') perspectives might be brought into decisions on intubation are currently unanswered questions. We report a 59-year-old woman with a background history of CREST syndrome (calcinosis, Raynaud phenomenon, (o)eso-phageal dysmotility, sclerodactyly and tel-angiectasia) and secondary pulmonary hypertension who presented with a bilateral lower limb vasculitic rash. A couple of weeks earlier she had been initiated on nebulised iloprost (Ventavis; Bayer New Zealand, Auckland, New Zealand) for progression of her pulmonary hypertension while on treatment with Sildenafil. She started on 20 mg three times a day, increasing every 3 days to a total of 20 mg every 4 h. Within a few days of reaching the maximum dose she developed a painful vasculitic rash over both lower limbs, which did not respond to analgesia and emollients (see fig 1). The dose of iloprost was reduced slowly over a couple of weeks to 15 mg three times a day. …
منابع مشابه
Anticoagulation and Iloprost for heparin-induced thrombocytopenia: a case report.
In patients who receive heparin for anticoagulation, there can be a mild, transient thrombocytopenia which is usually devoid of complications. However, 6% of these patients experience serious heparin-induced thrombocytopenia (HIT), which can result in coagulation problems or death. Iloprost, a recently developed drug, given in conjunction with heparin, can be used to manage the patient with HIT...
متن کاملIloprost improves endothelial barrier function in lipopolysaccharide-induced lung injury.
The protective effects of prostacyclin and its stable analogue iloprost are mediated by elevation of intracellular cyclic AMP (cAMP) leading to enhancement of the peripheral actin cytoskeleton and cell-cell adhesive structures. This study tested the hypothesis that iloprost may exhibit protective effects against lung injury and endothelial barrier dysfunction induced by bacterial wall lipopolys...
متن کاملRap1 mediates protective effects of iloprost against ventilator-induced lung injury.
Prostaglandin I(2) (PGI(2)) has been shown to attenuate vascular constriction, hyperpermeability, inflammation, and acute lung injury. However, molecular mechanisms of PGI(2) protective effects on pulmonary endothelial cells (EC) are not well understood. We tested a role of cAMP-activated Epac-Rap1 pathway in the barrier protective effects of PGI(2) analog iloprost in the murine model of ventil...
متن کاملPeroxisome proliferator-activated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation.
We have previously demonstrated that iloprost, a stable prostacyclin (PGI(2)) analogue, induces angiogenesis in vivo, through a vascular endothelial growth factor (VEGF)-dependent mechanism. In this study, we demonstrate that iloprost-induced angiogenesis and VEGF upregulation are modulated by peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-inducible transcription factor ...
متن کاملIloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
BACKGROUND The prevention of contrast-induced nephropathy, which accounts for considerable morbidity and mortality, remains a vexing problem. Contrast-induced renal vasoconstriction is believed to play a pivotal role in the pathogenesis of contrast-induced nephropathy. The aim of this study was to examine the efficacy of the prostacyclin analog iloprost in preventing contrast-induced nephropath...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Thorax
دوره 64 10 شماره
صفحات -
تاریخ انتشار 2009